Hedge fund managers are fuming at new political rhetoric against them and their huge paydays.» Read More
Herbalife stock dipped in after-hours trading right after the earnings were released, but then quickly rebounded.
A group of eight or so anti-Herbalife protesters gathered for a prayer vigil to oppose Carl Icahn's support of the stock.
Find out who gets an "A" or an "F" from investors in the hedge fund world.
It was man versus machine when Bill Ackman interviewed Ray Dalio in New York.
Bill Ackman professes big belief in the stock of housing giants Fannie Mae and Freddie Mac.
Hedge fund billionaire Larry Robbins gave investment ideas at a charity stock picking event in New York on Thursday.
Nearly three years after taking a substantial stake in the auto supplier, Marcato Capital Management is agitating for a breakup.
Bill Ackman appears set to take it easy for a few months after knockout performance in 2014.
Activist investor famous for his high-profile battle with Herbalife claims short was 'most philanthropic investment I have ever made.'
The hedge fund industry has two new massive independent money managers to start 2015: Leda Braga and David Warren.
Bill Ackman renewed his attack on Herbalife during a CNBC interview Wednesday, likening the nutrition and weight management company to Bernie Madoff.
Wall Street may not have Bill Ackman to kick around anymore.
Fresh of a big win from investing in human drugs, Bill Ackman is now focused on pharmaceuticals for animals.
Before you get too excited about Friday's move, "Mad Money" host Jim Cramer puts it in context.
Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.
Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.
Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.
Bill Ackman isn't the only hedge fund manager who likely made big money on the Allergan deal.
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
An unconfirmed rumor appears to be having a major impact on Wal-Mart options trading.